OBI Pharma
台灣浩鼎生技股份有限公司
OBI Pharma is a Taiwan TPEx-listed biotechnology company; its most advanced asset is OBI-858 (Phase 3 trials authorized, Moderate to severe glabellar lines), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| OBI-858 | — | Phase 3 trials authorized | Moderate to severe glabellar lines | Taiwan | 2025-08-22 | Company disclosure |
| OBI-902 | — | Phase 1 / Phase 2; recruiting | Advanced Solid Tumor | Taiwan, United States | 2026-01-05 | Trial registry |
| OBI-992 | TROP2 antibody-drug conjugate | Phase 1 / Phase 2; active not recruiting | Advanced Solid Tumor | Taiwan, United States | 2025-08-08 | Trial registry |
Key events
- OBI-3424 Phase 2 first-stage preliminary analysis reported by SWOG (company disclosure)
- OBI-902 received FDA orphan drug designation for gastric cancer (company disclosure)
Related Drugnews articles
Adding an ADC to Lung Cancer Immunotherapy: More Tumor Responses, but Why Did Phase 3 Fall Short?
The Next ADC War: Novartis Is Paying Up to $1.5 Billion for Myricx, but the Real Prize Is a New Payload Class
Winning First Is Not Winning: Roche's Divarasib Pushes KRAS Into a Generational Elimination Race